Anixa Biosciences Inc. announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,370,244 on July 29, 2025, covering significant aspects of its breast cancer vaccine technology. The patent protects innovative methods for immunizing patients against breast cancer using an immunogenic composition containing human α-lactalbumin protein. This development extends Anixa's intellectual property protection for its breast cancer vaccine program into the mid-2040s, reinforcing the company's position in preventive oncology. The vaccine, developed in collaboration with Cleveland Clinic, targets a substantial unmet need in cancer prevention, particularly for women at high risk of developing triple-negative breast cancer (TNBC).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.